List of Artificial Intelligence Companies in Washington - 41

A-Alpha Bio is a biotechnology company harnessing synthetic biology and machine learning to measure, predict, and engineer protein-protein interactions. Our experimental platform, AlphaSeq, enables the rapid and quantitative measurement of millions of protein-protein binding affinities simultaneously. Our computational platform, AlphaBind, is trained on the world’s largest protein-protein interaction database and predicts binding strength from sequence. A-Alpha Bio leverages AlphaSeq and AlphaBind for in-house therapeutic programs and in partnership with leading pharmaceutical companies to inform the discovery and development of novel therapeutics. A-Alpha Bio is based in Seattle and was founded in 2017 at the University of Washington's Institute for Protein Design and Center for Synthetic Biology. To learn more, please visit: https://www.aalphabio.com/

Absci is a generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation™ platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to learn, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed antibodies to wet lab-validated candidates in as little as six weeks. Our vision is to deliver breakthrough therapeutics at the click of a button, for everyone.

We help entrepreneurs form new teams and build AI-first startups. Apply on our website for $500k investment, up to $1M in free AI compute, and network of AI founders and researchers. We bring together world-class engineers, researchers, and entrepreneurs to create new companies together from scratch. From ideation to execution, we help generate ideas, find co-founders, secure pilot customers, integrate cutting-edge AI, and more. Our hands-on support guides founders through building, scaling, and raising millions in venture funding. In 6 years, we've backed 40+ companies now valued at $1B+, raising $220M+ and creating 700+ jobs. Our startups are transforming industries: improving immigrant communication (Yoodli), accelerating cancer research (Ozette and Modulus), enhancing legal efficiency (Lexion, acquired by DocuSign), turning smartphones into medical devices (PreemptiveAI), and so much more. Any VC can write a check, but what truly sets us apart is our unparalleled technical and AI expertise. With our heritage at the Allen Institute for AI—founded by Microsoft co-founder Paul Allen—we’ve been singularly focused on commercializing AI long before it became a buzzword. AI2 has 200+ PhDs, researchers, engineers, professors, and support staff—and is well known for its contributions to the A.I. research community including 600+ papers, 20+ best paper awards, and numerous products/open-source offerings including SemanticScholar, AllenNLP, and more. Our core team includes pioneers like Oren Etzioni, a leader in AI for over three decades, and our deep technical expertise means we don’t just back you financially—we help you build breakthrough products, navigate complex challenges, and accelerate your company’s growth. We're soon launching AI House in Seattle, a central hub for AI innovation. In partnership with the Mayor of Seattle and supported by Washington state, this space will serve as a central hub for the region’s AI community.

A.I. Analysis, Inc. is a medical software company specializing in the application of artificial intelligence (AI) to radiology. A.I. Analysis, Inc.’s first product is the Change Detector for Brain Imaging, a machine-learning based system that compares serial MR imaging studies and presents changes in the form of a color overlay superimposed on the anatomical images. The Change Detector saves radiologists time at the beginning of their reading — perhaps up to 10 minutes for diseases such multiple sclerosis. The Change Detector highlights the locations of changes and degree of those changes, so the radiologist can more quickly reach clinical judgments. Using the Change Detector, it may be possible for radiologists to detect changes months earlier than is possible with manual inspection alone, with greater reproducibility.

Aiberry is an AI-powered multimodal platform that offers providers and care managers rapid, objective, and unbiased behavioral health assessments. Aiberry delivers evidence-based insights virtually (in telehealth scenarios) and at the point of care, offering unique outreach and scale opportunities.

Aigen is accelerating the transition to regenerative agriculture. We're launching the world's first AI-driven, network connected robotic fleet, powered entirely by the elements. Aigen is building a future with no harmful chemicals in our food. Backed by NEA, GFC, AgFunder, Regen.vc, and Bessemer Ventures

Alli Connect is a mental health care service for first responders that proactively promotes wellness and positive change in public safety.

Archon is a biotechnology company developing computationally designed proteins to unlock powerful therapeutic targets that lie beyond the reach of existing modalities and to better treat disease. We directly apply generative protein design to create a new biologic class, Antibody Cages (AbCs), that integrates the industry-proven affinity and specificity of antibodies into self-assembling nanostructures. Precise control over AbC structure provides the ability to tune both how they distribute in the body and engage their cellular targets with high specificity and potency to establish a new gold-standard for biologic medicines.

Arzeda combines protein design, pathway design, HT screening and strain construction to create and improve designer fermentation strains for virtually any chemical. One example of their work is indeveloping new and improved enzymes to make rare sugars, natural sweeteners,and other oligosaccharides.

Cyrus Biotechnology is a biotechnology company that specializes in protein engineering and drug discovery through computational biology.

EchoNous creates transformative handheld point-of-care ultrasound solutions by infusing premium ultrasound performance with industry-leading AI educational tools providing more clinicians with increased information faster. Visit our website at https://www.echonous.com/ Explore a directory of our most popular content https://linktr.ee/echonous.kosmos

Genemod helps scientists maximize productivity in their research to drive the next generation of medicines. Genemod helps solve problems of data sharing and data archiving for research labs by providing inventory, experiment management, applications, and data, all in one collaborative workspace.

Gestalt transforms pathology through an intelligent, configurable, and vendor-neutral, AI-driven, digital workflow that provides true interoperability enabling pathologists to diagnose* diseases faster and more efficiently. Our PathFlow® solution is a cloud-based digital pathology enterprise platform that can easily be customized based on your specific preferences. This platform consists of professional, education, and research modules for ease of mixing and matching the digital needs of your facility in a single solution, freeing pathologists from tedious, repetitive, and manual tasks allowing them to focus on their expertise, providing their invaluable experience where it matters most. *Research Use Only (RUO) unless following CAP guidelines for LDT.

Meet your business challenges head on with cloud computing services from Google, including data management, hybrid & multi-cloud, and AI & ML.

InduPro is a biotechnology company that brings proteins on the cell surface closer together, manipulating their interactions and opening new possibilities for treating various conditions.

IndyGeneUS AI is a Black-Owned & Service-Disabled Veteran-Owned Small Business (SDVOSB) genomics company creating the world’s largest block-chain encrypted repository of indigenous and diasporic African clinical and multi-omics data for disease prevention/detection, drug discovery and development, clinical disease management, and precision health equity.

Koidra is an intelligent automation company, dedicated to modernizing the automation of manufacturing facilities, with the high-tech greenhouse industry being the core market. Our tiered products deliver a comprehensive solution that enhances industrial efficiency.

Küleon is a drug discovery company leveraging proprietary, AI-based technology to identify novel serotonergic drugs for the targeted treatment of various neuropsychiatric diseases and disorders. We’ve created a proprietary portfolio of serotonin receptor ligands designed to target neurocircuit abnormalities in the brain that are responsible for difficult-to-treat disorders such as schizophrenia and depression. We have successfully identified several preclinical leads that have significantly improved agonism characteristics such as low-to-no hallucinogenic or cardiotoxic liability, as well as modified PK/PD profiles when compared to other known atypical antipsychotics and serotonergic drugs. Serotonergic drugs have the potential to address multiple indications affecting large population groups that make up extremely sizable markets. This is because many of the current SSRIs and non-selective serotonin receptor agonists were not designed with an eye towards functional selectivity. Our novel compounds are designed for functional selectivity via biased signalling mechanisms, potentially enhancing their therapeutic effect and reducing unwanted side effects. Our proprietary molecular scaffolds and compounds are novel and patentable, providing us with a tremendous strategic foothold in the market as companies continue to explore novel mechanisms of action for targeting neuropsychiatric diseases and disorders. We are collaborating with some of the world’s leading academic researchers and key opinion leaders in the serotonergic and atypical antipsychotic drug development space. Please reach out if you would like learn more about the work we are doing with our collaborators!

For organizations committed to providing the best behavioral health, human services, or wellness care, Lyssn's AI is the modern evidence-based quality improvement and training solution that provides visibility into human interactions and integrates expert-developed best practices so organizations can measure, train, and improve evidence-based practice at scale while meeting regulatory requirements. And, Lyssn requires dramatically less labor than current approaches with superior results at lower cost.

Microsoft is a technology company that offers a wide range of software, cloud computing services, hardware, and artificial intelligence solutions.

Ora Biomedical, Inc. is a new pharmaceutical company in the longevity biotechnology sector that identifies and characterizes healthy aging therapeutics for further clinical and commercial development. Ora Biomedical separates itself from other longevity biotech companies by building in large-scale drug discovery and validation at the core of our scientific operations. With robust preclinical discovery at the heart of our approach, we identify novel aging targets and new interventions for known targets. Most importantly, we will leverage large-scale operations to perform drug studies that combine known and novel healthy aging interventions to identify those that produce breakthrough increases in healthy lifespan and/or mitigate disease-mediated pathology.

Outpace is creating cell therapies with curative potential through protein design and cellular engineering. With an initial focus on solid tumors, Outpace is developing technologies that overcome the barriers to efficacy and safety by programming cells to make the right decisions inside patients. Outpace’s suite of technologies drive persistent activity of the cell therapy (OutLast™), recruit a productive immune response in the tumor microenvironment (OutSmart™), and achieve the potency (OutSpacers™), specificity (Co-LOCKR™), and safety (EGFRopt™) necessary to unlock diverse cancer indications. Outpace’s internal and partnered pipeline approach is optimized for rapid clinical validation of its technologies across diverse cell types and manufacturing processes. At Outpace Bio, we believe that the highest performing teams include people from a wide variety of backgrounds and experiences who respectfully challenge each other. We are committed to building an open, diverse, and inclusive culture for all employees.

Developing a single cell immunoprofiling platform.The company’s tools quantify and assess what types of cells are in samples based on the composition of surface proteins.

Pacific Northwest National Laboratory advances the frontiers of knowledge, taking on some of the world’s greatest science and technology challenges. PNNL is a U.S. Department of Energy national lab with distinctive strengths in chemistry, Earth sciences, biology, and data science that are central to our scientific discovery mission. PNNL’s research lays a foundation for innovations that advance sustainable energy through decarbonization and energy storage and enhance national security through nuclear materials and threat analyses. PNNL collaborates with academia in its fundamental research and with industry to transition technologies to market.

Pattern Computer, Inc., a Seattle-area AI & ML company, uses its proprietary Pattern Discovery Engine™ to solve the most important and most intractable problems in business and medicine. Its proprietary mathematical techniques can find complex patterns in very-high-order data that have eluded detection by much larger systems. As the Company applies its computational platform to the challenging fields of drug discovery and diagnostics, it is also making major pattern discoveries for partners in other sectors, including biotech, materials science, aerospace manufacturing, veterinary medicine, air traffic operations, and finance. Highlights: • Innovative / Proprietary Technology • Pattern Discovery Engine™ discovers and generates valuable hypotheses and insights into complex data, revealing novel patterns that cannot be discovered using conventional techniques or tools • Pattern produces exceptionally valuable assets within some of the most fiercely competitive domains … and commercializes them • Multiple high-growth markets: immediate focus most daunting yet immediate promise for life-changing & life-saving contributions to society including: • Life Sciences • XAI • Commercial Journey along with us as we move from creating our high-value assets to capitalization/commercialization of them- taking AI by storm with our focus on Third Wave AI.

Phenome Health is a research organization dedicated to preventing disease and taking the guesswork out of healthcare. We are driving a revolution by moving past the disease-focused “find it and fix it” era to wellness and prevention that enables all of us to live longer and healthier lives.

Photon Biosciences' core technology is a new ultrasensitive detection platform that combines bioengineered proteins with a uniquein vivobiomineralization process that results in a number of different genetically expressible luminescent bionanoparticles that are non-bleaching and non-blinking with luminescence intensities that rivals and surpasses many fluorescent organic molecules. The excitation and emission wavelengths of these expressible bionanoparticles can be tuned with the composition of the mineralization process and span much of the visible and near infrared regions of the electromagnetic spectrum. Because of its unique photophysical properties, PBS® has been developed into new ultrasensitive probes for biomolecular research, detection technologies, and cellular imaging.The company is developing a test to detect contamination in donated platelets.

Prevencio is Revolutionizing Blood Tests For Cardiovascular Disease || Powered by Artificial Intelligence (AI) || Preventative Medicine for Heart Health Prevencio's purpose is to prevent the preventable. 80% of cardiovascular disease, including heart disease and stroke, are preventable (CDC). Prevencio's personalized blood tests provide earlier detection and prevention which can diminish unnecessary procedures and related side effects, as well as improve patient outcomes. Published in top-tier cardiology journals and presented at leading cardiovascular meetings, Prevencio's patented, proprietary technology has been used to create seven life-saving cardiovascular tests, with more in development.   Prevencio utilizes Machine Learning (Artificial Intelligence) + Multi-Proteomic Biomarkers + Proprietary Algorithms to deliver cardiovascular diagnostic & prognostic tests that are significantly more accurate than standard-of-care stress tests, individual biomarkers, genetic markers and clinical risk scores. To learn more visit us at: www.prevenciomed.com

Remmie Health is a digital health technology venture that delivers next-generation, AI-enabled, ear-nose-throat care for easier, accessible diagnosis, timely intervention, and exceptional patient care. Remmie is a patient-centric, primary care telemedicine/at-home examination device + API + AI system that enables patients/consumers to receive virtual/hybrid care from healthcare professionals, covering 22+ most commonly occurring respiratory conditions, causing over 120 million annual visits as the leading reason for ambulatory care, impacting every family 2-9 times a year. The winner of the Muse Innovation Fellowship, UCLA Knapp Venture Competition, and Rice Business Plan Competition, Remmie Health is a UnitedHealthcare Accelerator (powered by Techstars) and Plug and Play portfolio company. The company is based in Seattle, WA.

Sage Bionetworks is a trusted nonprofit leader in data sharing and reuse, enabling a rapid acceleration in biomedical discoveries and the transformation of medicine. Our mission is to drive a new age of discovery through truly open science and radical collaboration. Better Science Together.

Sana Biotechnology is focused on utilizing engineered cells as medicines for patients. The ability to modify genes and use cells as medicines will be one of the most important advances in healthcare over the next several decades. Sana is building differentiated capabilities across the spectrum of cell and gene therapy. Three aspirations drive Sana as we look to discover treatments for patients with poor outcomes or currently untreatable diseases. The first is the ability to repair and control the genes in any cell in the body. We are advancing novel delivery technologies with the goal of being able to deliver any payload to any cell in a specific, predictable, and repeatable manner, paving the way for next-generation in vivo gene therapy. Next is the ability to differentiate pluripotent stem cells ex vivo into immune-cloaked functional cells with the aspiration of being able to replace any missing or damaged cells in the body. Last is a belief we can enable broader access to our therapies through focusing on scalable manufacturing solutions, the cost of manufacturing, and aligning with key stakeholders. Sana launched in early 2019 and has over 350 employees in Seattle, Cambridge, and South San Francisco. Sana was founded with the long view – bringing together great people and the best technologies to deliver on the challenging promise of using engineered cells to meaningfully change the outcome of many human diseases.

Shape Therapeutics is a biotechnology company that combines breakthroughs in AI, RNA technology, and synthetic biology to create safe, effective, and accessible medicines to help as many patients as possible. The company was founded with the mission to make programmable RNA medicines available for everyone. Shape Therapeutics is pioneering the field of programmable RNA Medicines.

SoundHealth is on a mission to help the world breathe free. As a startup, we specialize in AI-based, personalized, drug-free treatment designed to improve respiratory health. SoundHealth is founded by an experienced team of serial entrepreneurs in the technology and medical fields. SoundHealth's inaugural product, SONU, is the world's first FDA-authorized wearable device offering drug-free, spray-free, personalized relief from nasal congestion.

Talus Bioscience is a venture-backed early-stage biotechnology startup company working on drug development for gene regulators. Talus Bio spun out of two leading institutions in September 2020 (University of Washington and Altius Institute for Biomedical Sciences) and is located in Seattle, WA. We are building a data-enabled drug development platform that will focus primarily on small-molecule drug development in oncology. Talus Bio's platform measures a drug’s ability to disrupt a gene regulator within its natural, non-engineered cellular environment. Furthermore, a single experiment using the platform measures activity for about 1,000 gene regulators simultaneously, providing information on in-cell drug activity and specificity in a single experiment. To accomplish this, we combine innovative cell processing with high-sensitivity quantitative proteomics and advanced downstream analytics. As a company, Talus Bio focuses on two parallel efforts to prove that our technology can open up the world of gene regulation for drug discovery: - Developing internal programs against previously undruggable gene regulators in cancers with poor standard of care - Partnering with pharma, biotech, and academic labs to help progress their pipeline of gene regulator drugs

Truveta is a growing collective of health systems in the US with a mission of Saving Lives with Data. Truveta delivers the most complete, clean, and timely regulatory-grade EHR data for scientifically rigorous research. Truveta is trusted by leading life science, government, health system, academic and research organizations to accelerate adoption of new therapies, improve clinical trials, and enhance patient care.

Vilya is a computational biotechnology company creating a novel class of medicines to precisely target disease biology. The company’s proprietary platform, powered by advanced machine learning, taps into uncharted chemical space to design de novo molecular structures with enhanced drug-like properties that range in size between small molecules and antibodies. Vilya is leveraging its platform to focus on previously difficult-to-drug therapeutic targets. Vilya was co-founded by a team of scientists from the Institute of Protein Design (IPD) led by David Baker, Ph.D., and ARCH Venture Partners. The company has operations in Seattle and South San Francisco.

We are developing a platform for discovery of RNA-targeting small molecules to treat genetic diseases, neurodegeneration and cancer. We combine a proprietary high-throughput screening platform with machine learning models and unique datasets to accelerate development of drugs for previously undruggable targets. https://wayfinderbio.com

Wisecube: Revolutionizing AI Trustworthiness and Insights for Highly Regulated Industries Wisecube, founded by AI and data experts, we are a startup specializing in Open and Trustworthy AI for highly regulated industries like finance, pharma, and healthcare. Our mission is to revolutionize AI trustworthiness and insights through open-source semantic data solutions. AI has a trust problem. Hallucinations or factual inaccuracies generated by Large Language Models (LLMs) can lead to: • Stakeholder Confidence Issues: Frequent hallucinations can erode trust in AI technologies. • Compliance Violations: LLMs can perpetuate harmful stereotypes and social stigmas, potentially leading to discrimination and compliance issues. • Errors in Critical Decisions: Hallucinations can lead to erroneous decisions in critical fields like medicine, finance, and policy. The Wisecube Solution Our solution centers around the semantic modeling of data, decomposing LLM responses into semantic triplets to test the factualness of individual knowledge points. This approach provides more informative and precise insights than traditional methods that analyze paragraphs or sentences. Our Products An open-source Trustworthy AI platform that offers: • Simplified knowledge graph construction for contextual insights. • State-of-the-art open-source AI hallucination detection. • Interactive prompt engineering and active learning features. • Centralized model registry and streamlined model deployments. • Open-source API access and unified governance. • Private Cloud deployment support. Investment Highlights • Experienced team with a proven track record in AI and data science. • Addressing a critical need for trustworthy AI solutions in high-stakes industries. • Innovative technology with a strong focus on open-source collaboration. • Successful case studies demonstrating the value and impact of our solutions.

Yoneda Labs is an AI-based software company that assists chemists in optimizing reaction parameters such as temperature, concentration, and catalyst. The company's platform helps to figure out the reaction parameters without wet lab experimentation, and then can help optimize if necessary.

ZipBio is a biotech startup revolutionizing AI drug discovery with our cutting-edge protein design and drug discovery platform. We specialize in compressing biology to accelerate therapeutic innovation.